Table 1.
Overall survival, stratified by etiology, in select phase III studies evaluating HCC systemic therapies
| Trial name | Treatment arms | Trial aetiology | OS HR (95% CI) | |
|---|---|---|---|---|
| 1st line | ||||
| SHARP [115] | Sorafenib vs. placebo | HBV (n=111, 18%) | 0.76 (0.38-1.50) | |
| HCV (n=169, 28%) | 0.50 (0.32-0.77) | |||
| Alcohol (n=159, 26%) | 0.76 (0.50-1.16 | |||
| Asia-Pacific [116] | Sorafenib vs. placebo | HBV +ve (n=165, 73%) | 0.74 (0.51-1.06) | |
| HBV -ve (n=61, 27%) | 0.57 (0.29-1.13) | |||
| REFLECT [119] | Lenvatinib vs. sorafenib | HBV (n=479, 50%) | 0.83 (0.68-1.02) | |
| HCV (n=217, 23%) | 0.91 (0.66-1.26) | |||
| Alcohol (n=57, 6%) | 1.03 (0.47-2.28) | |||
| IMbrave150 [122] | Atezolizumab + bevacizumab vs. sorafenib | HBV (n=240, 48%) | 0.51 (0.32-0.81) | |
| HCV (n=108, 22%) | 0.43 (0.22-0.87) | |||
| Non-viral (n=153, 31%) | 0.91 (0.52-1.60) | |||
| HIMALAYA [124] | Tremelimumab + durvalumab vs. sorafenib | HBV (n=241, 31%) | 0.64 (0.48-0.86) | |
| HCV (n=214, 27%) | 1.06 (0.76-1.49) | |||
| Non-viral (n=327, 42%) | 0.74 (0.57-0.95) | |||
| 2nd line | ||||
| RESORCE [125] | Regorafenib vs. placebo | HBV (n=216, 38%) | 0.58 (0.41-0.82) | |
| HCV (n=119, 21%) | 0.79 (0.49-1.26) | |||
| Alcohol (n=145, 25%) | 0.92 (0.61-1.38) | |||
| CELESTIAL [126] | Cabozantinib vs. placebo | HBV (n=267, 38%) | 0.69 (0.51-0.94) | |
| HCV (n=168, 24%) | 1.11 (0.72-1.71) | |||
| Non-viral (n=272, 38%) | 0.72 (0.54-0.96) | |||
| REACH-2 [127] | Ramucirumab vs. placebo | HBV (n=107, 37%) | 0.84 (0.52-1.35) | |
| HCV (n=76, 26%) | 0.76 (0.44-1.33) | |||
| Other (n=109, 37%) | 0.63 (0.38-1.06) | |||
| KEYNOTE-240 [121] | Pembrolizumab vs. placebo | HBV (n=101, 24%) | 0.57 (0.35-0.94) | |
| HCV (n=64, 15%) | 0.96 (0.48-1.92) | |||
| Non-viral (n=248, 60%) | 0.88 (0.64-1.20) | |||
HCC, hepatocellular carcinoma; OS, overall survival; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.